Bevacizumab clearance through the iridocorneal angle following intravitreal injection in a rat model. (April 2016)

• Record Type: Journal Article
• Authors: Gal-Or, Orly; Dotan, Assaf; Dachbash, Mor; Tal, Kfir; Nisgav, Yael; Weinberger, Dov; Ehrlich, Rita; Livnat, Tami
• Is Part Of: Experimental eye research. Volume 145(2016:Apr.)
• Page Start: 412
• Page End: 416
• Publication Date: 2016-04
• Subjects: Bevacizumab -- Trabecular meshwork -- Schlemm's canal -- Clearance -- Intraocular pressure; Choroidal neovascularization CNV -- vascular endothelial growth factor VEGF -- age-related macular degeneration AMD -- intraocular pressure IOP -- trabecular meshwork TM -- Schlemm's canal SC -- normal donkey serum NDS -- Immunoreactivity IR; Ophthalmology -- Periodicals; Eye -- Periodicals; Œil -- Périodiques; Ophthalmology; Periodicals; Electronic journals; 612.8405
• DOI: 10.1016/j.exer.2016.02.006
• Languages: English
• ISSNs: 0014-4835

Abstract

Abstract: Antivascular endothelial growth factor (Anti-VEGF) agents have been widely used for a variety of ocular disorders. The etiology of sustained ocular hypertension following intravitreal administration of anti-VEGF agents is yet to be unraveled. Our study investigates and characterizes the presence of intravitreally injected bevacizumab in the aqueous outflow channels of a rat model. Choroidal neovascularization (CNV) was induced by diode laser photocoagulation to the right eye of twelve Brown Norway rats. Bevacizumab (25 mg/ml) was injected intravitreally after 3 days. Immediately after bevacizumab injection, and 3, 6, 24 and 48 h later, animals were euthanized for immunofluorescence staining. Donkey anti-human IgG labeled with Alexa Fluor ® 488 was used for bevacizumab immunoreactivity detection. Anti-CD31 antibody was used as a marker for Schlemm's canal endothelial cells. Untreated eyes were used as negative controls. The intensity of the immunostaining was analyzed qualitatively. Bevacizumab immunoreactivity was found in the aqueous outflow channels including the trabecular meshwork and Schlemm's canal immediately after injection, and declined incrementally within the following hours. Forty-eight hours after the injection, no bevacizumab staining was detected in the aqueous outflow channel structures. Our manuscript demonstrates the presence of bevacizumab in the trabecular meshwork and Schlemm's canal structures after intravitreal injection in a CNV induced rat model. Bevacizumab molecules passed through the aqueous outflow channels within 48 h after intravitreal bevacizumab injection. Highlights: Analysis of intravitreal Bevacizumab clearance was proposed in a rat model. Aqueous outflow channels were analyzed for bevacizumab Immunoreactivity. Immunoreactivity was demonstrated in trabecular meshwork and Schlemm's canal. Intravitreal bevacizumab passed through the aqueous outflow channels within 48 h.